ArticleCancer research2022
Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 21 citations in OpenAlex.
- PKM2 modulation regulates leukemia cell survival.Cancer & metabolism · 2026Article
- Compartmentalized glycolysis powers ATP production in primary cilia and engages mitochondria via the phosphoenolpyruvate cycle.bioRxiv : the preprint server for biology · 2026Article
- ASO-based PKM splice-switching therapy increases anti-CTLA-4 antibody efficacy in pancreatic ductal adenocarcinoma.Cell discovery · 2026Article
- PKM1 is required for embryonic cardiomyocyte proliferation through energetic regulation of NFYa stability.National science review · 2026Article
- Liquid biopsy in breast cancer: Redefining precision medicine.The journal of liquid biopsy · 2025Review
- Nudix Hydrolase 13 Impairs the Initiation of Colorectal Cancer by Inhibiting PKM1 ADP-Ribosylation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Deciphering Complexity: The Molecular Landscape of Castration-Resistant Prostate Cancer.Surgical pathology clinics · 2025Review
- Fructose Metabolism in Cancer: Molecular Mechanisms and Therapeutic Implications.International journal of medical sciences · 2025Review
- The Role of PKM2 in Multiple Signaling Pathways Related to Neurological Diseases.Molecular neurobiology · 2024Review
- A Compound That Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer.Molecular cancer therapeutics · 2024Article
- The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissues.bioRxiv : the preprint server for biology · 2024Article
- ROCK Inhibitor Fasudil Attenuates Neuroinflammation and Associated Metabolic Dysregulation in the Tau Transgenic Mouse Model of Alzheimer's Disease.Current Alzheimer research · 2024Article
- The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissues.Frontiers in oncology · 2024Article
- Biological role of fructose in the male reproductive system: Potential implications for prostate cancer.The Prostate · 2024Review
- Neurons require glucose uptake and glycolysis in vivo.Cell reports · 2023Article
- Proteomic analysis of holocarboxylase synthetase deficient-MDA-MB-231 breast cancer cells revealed the biochemical changes associated with cell death, impaired growth signaling, and metabolism.Frontiers in molecular biosciences · 2023Article
- Aberrant expression of multiple glycolytic enzyme genes is significantly associated with disease progression and survival outcomes in prostate cancers.American journal of clinical and experimental urology · 2023Article
- Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer.Biomolecules · 2022Review
- Article
- PKM1 Exerts Critical Roles in Cardiac Remodeling Under Pressure Overload in the Heart.Circulation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 8 institutions in 2 countries.
Shawn M DavidsonKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Daniel R Schmidt *Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0001-6192-0378
Julia E Heyman *Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
James P O'Brien *Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Amy C Liu *Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
William J IsraelsenKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0002-3653-9353
Talya L DaytonKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0002-7994-7963
Raghav SehgalElucidata, Cambridge, Massachusetts.
Roderick T BronsonKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Elizaveta FreinkmanWhitehead Institute, Cambridge, Massachusetts.
Howard H MakKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0003-2031-4472
Giuseppe Nicolò FanelliWeill Cornell Medical College, New York, New York.ORCID 0000-0001-7069-7980
Scott MalstromKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Gary BellingerKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Arkaitz CarracedoBeth Israel Deaconess Medical Center, Boston, Massachusetts.ORCID 0000-0001-5957-1260
Pier Paolo PandolfiBeth Israel Deaconess Medical Center, Boston, Massachusetts.
Kevin D CourtneyDana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-6273-3144
Abhishek JhaElucidata, Cambridge, Massachusetts.ORCID 0000-0002-1489-2471
Ronald A DePinhoDana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-5625-577X
James W HornerDana-Farber Cancer Institute, Boston, Massachusetts.
Craig J ThomasNational Center for Advancing Translational Sciences, NIH, Bethesda, Maryland.ORCID 0000-0001-9386-9001
Lewis C CantleyBeth Israel Deaconess Medical Center, Boston, Massachusetts.ORCID 0000-0002-1298-7653
Massimo LodaWeill Cornell Medical College, New York, New York.ORCID 0000-0001-9674-8379
Matthew G Vander HeidenKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0002-6702-4192
Massachusetts Institute of Technology · USBeth Israel Deaconess Medical Center · USBroad Institute · USDana-Farber Cancer Institute · USCornell University · USNational Center for Advancing Translational Sciences · USUniversity of Pisa · ITWhitehead Institute for Biomedical Research · US
Funding
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Andreea O'Connell · 1985 to 2026
$93.9MPRE-DOCTORAL TRAINING IN THE BIOLOGICAL SCIENCEST32GM007287 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BELL, STEPHEN P., KEATING, AMY E · 1985 to 2019
$40.8MTumor and Circulating Markers as Links Between Obesity and Lethal Prostate CanceP50CA090381 · NCI · DANA-FARBER CANCER INSTITUTE · PI KANTOFF, PHILIP W · 2002 to 2017
$36.2MRole of Phosphoinositides and Protein Kinases in the control of Cancer MetabolismR35CA197588 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEWIS C. CANTLEY · 2016 to 2026
$10.2MInstitutional Career Development CoreKL2TR002542 · NCATS · HARVARD MEDICAL SCHOOL · PI BREDELLA, MIRIAM ANTOINETTE, RUTKOVE, SEWARD B. · 2018 to 2022
$8.7MUnderstanding the role of metabolism in cancerR35CA242379 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2019 to 2025
$5.8MNovel small molecule library developmentZIATR000043 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI THOMAS, CRAIG · 2015 to 2025
$3.3MRegulation of glucose metabolism to allow tumor initiation and growthR01CA168653 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2013 to 2019
$1.9MMouse Models to Evaluate the Role of Pyruvate Kinase Regulation in Cancer BiologyK08CA136983 · NCI · DANA-FARBER CANCER INST · PI VANDER HEIDEN, MATTHEW G. · 2008 to 2009
$279kHoward Hughes Medical InstituteNCATS NIH HHS KL2 TR002542NCI NIH HHS K08 CA136983NCI NIH HHS P30 CA014051NCI NIH HHS P50 CA090381NCI NIH HHS R01 CA168653NCI NIH HHS R35 CA197588NCI NIH HHS R35 CA242379NIGMS NIH HHS T32 GM007287
Abstract
significanceDifferential expression of PKM1 and PKM2 impacts prostate tumorigenesis and suggests a potential therapeutic vulnerability in prostate cancer.
Indexed as
AdenocarcinomaProstatic NeoplasmsCarcinogenesisHumansMaleProstatePyruvate KinasePyruvate Kinase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.